Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote & News

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 264 4280

Fax: 857 264 4299

Website: rhythmtx.com

Address:

222 Berkeley Street, 12th Floor, Boston, United States

AtomicAIerts Dec. 5 at 7:29 AM

$RYTM AtomicAlerts Scalp Alert Direction: SHORT Entry: $105.68 TP1: $104.98 | TP2: $104.28 | TP3: $103.58 Stop Loss: $106.28 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 2:36 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $110C Entry: 7.40 Exit: 13.65 Return: +84.46% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 9:09 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $110C Entry: 7.40 Exit: 13.65 Return: +84.46% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

abcdzepeda Dec. 4 at 7:50 PM

$RYTM does anyone here know when the EU is expected to render their decision on the approval of IMCEVRE for HO?

1 · Reply

TeeMan123 Dec. 4 at 2:08 PM

$RYTM interesting, just realized RYTM has skipped a few conferences where they're covered by analysts (Jefferies the week of Nov 17; Citi this week). Makes me wonder if the PWS data is closer than we think. Also interesting timing to be skipping conferences heading into JPM26 with all the buyout speculation (RYTM never attends JPM)

0 · Reply

Iightning Dec. 4 at 4:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $105C Entry: 9.45 Exit: 13.61 Return: +44.01% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Stonky_Mcprofitface Dec. 3 at 9:46 PM

$RYTM You have to add during those first-half-hour dips on this one.

0 · Reply

Hognose Dec. 3 at 3:06 PM

$RYTM adding.

0 · Reply

Iightning Dec. 3 at 9:09 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $80C Entry: 3.65 Exit: 4.96 Return: +35.98% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Quantumup Dec. 2 at 9:29 PM

Raymond James🏁 $AARD Strong Buy/$47 $SLNO $RYTM $LLY $NVO VKTX Here's what Raymond James said in its initiation report: https://x.com/Quantumup1/status/1995967645267771758?s=20

1 · Reply

Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress

Nov 10, 2025, 7:00 AM EST - 24 days ago

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

Nov 8, 2025, 11:48 AM EST - 26 days ago

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Nov 7, 2025, 7:30 AM EST - 27 days ago

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Nov 5, 2025, 4:01 PM EST - 4 weeks ago

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Nov 4, 2025, 8:06 PM EST - 4 weeks ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 4 weeks ago

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Oct 21, 2025, 4:01 PM EDT - 6 weeks ago

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Sep 24, 2025, 5:07 PM EDT - 2 months ago

Rhythm Pharmaceuticals, Inc. - Special Call

Sep 21, 2025, 10:45 AM EDT - 2 months ago

2 Under-the-Radar Stocks That Could Soar

TERN

Sep 9, 2025, 2:04 PM EDT - 3 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 4:01 PM EDT - 3 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Aug 20, 2025, 4:01 PM EDT - 3 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Aug 5, 2025, 6:58 PM EDT - 4 months ago

Rhythm (RYTM) Q2 Revenue Jumps 67%

Aug 5, 2025, 5:26 PM EDT - 4 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 4 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Jul 22, 2025, 4:01 PM EDT - 4 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Jul 18, 2025, 10:45 AM EDT - 4 months ago

Rhythm Pharmaceuticals CFO Sells 42,120 Shares

Jul 12, 2025, 6:00 PM EDT - 5 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Jul 10, 2025, 3:39 PM EDT - 5 months ago

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Jul 10, 2025, 6:21 AM EDT - 5 months ago

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Jul 9, 2025, 4:16 PM EDT - 5 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Jul 8, 2025, 4:01 PM EDT - 5 months ago

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Jun 30, 2025, 11:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

May 14, 2025, 8:00 AM EDT - 7 months ago

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 7, 2025, 3:21 PM EDT - 7 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 7 months ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Apr 23, 2025, 8:00 AM EDT - 8 months ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 8, 2025, 1:38 PM EDT - 8 months ago

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 7, 2025, 7:11 AM EDT - 8 months ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:00 AM EDT - 8 months ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Apr 6, 2025, 12:00 PM EDT - 8 months ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Mar 31, 2025, 2:05 PM EDT - 8 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY VRTX XENE

Mar 20, 2025, 4:01 PM EDT - 9 months ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Mar 19, 2025, 4:01 PM EDT - 9 months ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Mar 18, 2025, 7:00 AM EDT - 9 months ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Feb 26, 2025, 1:46 PM EST - 10 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 10 months ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 11:21 AM EST - 10 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 13, 2025, 8:00 AM EST - 10 months ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Jan 10, 2025, 7:15 AM EST - 11 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Dec 20, 2024, 2:24 PM EST - 1 year ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Dec 20, 2024, 2:15 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Dec 3, 2024, 6:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Nov 18, 2024, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Nov 13, 2024, 6:30 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Nov 13, 2024, 4:01 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 5, 2024, 10:45 PM EST - 1 year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

AtomicAIerts Dec. 5 at 7:29 AM

$RYTM AtomicAlerts Scalp Alert Direction: SHORT Entry: $105.68 TP1: $104.98 | TP2: $104.28 | TP3: $103.58 Stop Loss: $106.28 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 2:36 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $110C Entry: 7.40 Exit: 13.65 Return: +84.46% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 9:09 PM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $110C Entry: 7.40 Exit: 13.65 Return: +84.46% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

abcdzepeda Dec. 4 at 7:50 PM

$RYTM does anyone here know when the EU is expected to render their decision on the approval of IMCEVRE for HO?

1 · Reply

TeeMan123 Dec. 4 at 2:08 PM

0 · Reply

Iightning Dec. 4 at 4:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $105C Entry: 9.45 Exit: 13.61 Return: +44.01% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Stonky_Mcprofitface Dec. 3 at 9:46 PM

$RYTM You have to add during those first-half-hour dips on this one.

0 · Reply

Hognose Dec. 3 at 3:06 PM

$RYTM adding.

0 · Reply

Iightning Dec. 3 at 9:09 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RYTM Contract: Dec 19 $80C Entry: 3.65 Exit: 4.96 Return: +35.98% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Quantumup Dec. 2 at 9:29 PM

Raymond James🏁 $AARD Strong Buy/$47 $SLNO $RYTM $LLY $NVO VKTX Here's what Raymond James said in its initiation report: https://x.com/Quantumup1/status/1995967645267771758?s=20

1 · Reply

Hognose Dec. 2 at 8:08 PM

$RYTM great spot to start adding. Perceptive advisors and Ra has a huge holding in this.

0 · Reply

TeeMan123 Dec. 2 at 7:07 PM

$RYTM my base case on pws is that on Dec 12 at the close we get a PR that the data will be revealed on Monday Dec 15 with a pre-market call. I'm expecting positive outcome given Meeker's history as a drug developer, he never has pushed forward a drug that doesn't stand a strong chance of success, we can't predict the future but there is no person better able to gauge likelihood of success than Meeker.

1 · Reply

Hognose Dec. 2 at 3:47 PM

$RYTM $ASND

0 · Reply

CharlieeMungerTWITS Dec. 2 at 3:41 PM

$RYTM

0 · Reply

Iightning Dec. 1 at 11:04 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $RYTM **Contract:** Dec 19 $110C **Entry:** 9.12 **Exit:** 12.50 **Return:** **+36.96% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Stonky_Mcprofitface Dec. 1 at 8:14 PM

$RYTM

0 · Reply

Stonky_Mcprofitface Nov. 30 at 3:51 AM

$RYTM This may hit $130 next week.

2 · Reply

abcdzepeda Nov. 28 at 5:43 PM

$RYTM December cannot come soon enough, waiting for that PWS data read out!

0 · Reply

Hognose Nov. 26 at 3:29 PM

$RYTM nice base. Huge inst ownership on this one too. Buying.

0 · Reply

Iightning Nov. 26 at 1:51 AM

1ightning® Options Trade Alert (Actionable) | Buy $RYTM Dec 19 $110 Call | Enter: $9.07 Exit: $16.51 | Profit: 81.97% ROI | https://1ightning.com

0 · Reply

CharlieeMungerTWITS Nov. 25 at 2:19 PM

$RYTM $136!

0 · Reply

JarvisFlow Nov. 25 at 2:16 PM

Citigroup updates rating for Rhythm Pharmaceuticals ( $RYTM ) to Buy, target set at 136.

0 · Reply

Market Cap	6.77B
Revenue (ttm)	130.13M
Net Income (ttm)	-260.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-200.26%
Debt to Equity Ratio	0.00

Volume	575,800
Avg Vol	648,036
Day's Range	N/A - N/A
Shares Out	66.74M
Stochastic %K	63%
Beta	1.96
Analysts	Strong Sell
Price Target	$127.07